BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, He Y, Lu L, Zhou Z, Wan N, Li G, He X, Deng H. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A. Kaohsiung J Med Sci 2019;35:17-23. [DOI: 10.1002/kjm2.12004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Gong F, Li X, Zhang H, Wu J, Ma G, Zhang B, Gao J, Ding Y, Huang Y, Xia K, Cheng S, Zhou X, Shi J, Zhao F, Chen G. MiR-192-5p Alleviated Fibrosis and Inflammatory Responses of Tendon Cells by Targeting NFAT5. Computational and Mathematical Methods in Medicine 2022;2022:1-11. [DOI: 10.1155/2022/6481846] [Reference Citation Analysis]
2 Si Z, Zhong Y, Lao S, Wu Y, Zhong G, Zeng W. The Role of miRNAs in the Resistance of Anthracyclines in Breast Cancer: A Systematic Review. Front Oncol 2022;12:899145. [PMID: 35664800 DOI: 10.3389/fonc.2022.899145] [Reference Citation Analysis]
3 Shi H, Xu H, Chai C, Qin Z, Zhou W. Integrated bioinformatics analysis of potential biomarkers for pancreatic cancer. Clinical Laboratory Analysis. [DOI: 10.1002/jcla.24381] [Reference Citation Analysis]
4 Lahooti B, Poudel S, Mikelis CM, Mattheolabakis G. MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential. Front Oncol 2021;11:705634. [PMID: 34956857 DOI: 10.3389/fonc.2021.705634] [Reference Citation Analysis]
5 Jain N, Das B, Mallick B. miR-197-5p increases Doxorubicin-mediated anticancer cytotoxicity of HT1080 fibrosarcoma cells by decreasing drug efflux. DNA Repair (Amst) 2021;109:103259. [PMID: 34871862 DOI: 10.1016/j.dnarep.2021.103259] [Reference Citation Analysis]
6 Tian JH, Liu SH, Yu CY, Wu LG, Wang LB. The Role of Non-Coding RNAs in Breast Cancer Drug Resistance. Front Oncol 2021;11:702082. [PMID: 34589423 DOI: 10.3389/fonc.2021.702082] [Reference Citation Analysis]
7 Fu S, Ma C, Tang X, Ma X, Jing G, Zhao N, Ran J. MiR-192-5p inhibits proliferation, migration, and invasion in papillary thyroid carcinoma cells by regulation of SH3RF3. Biosci Rep 2021;41:BSR20210342. [PMID: 34486645 DOI: 10.1042/BSR20210342] [Reference Citation Analysis]
8 Torki Z, Ghavi D, Hashemi S, Rahmati Y, Rahmanpour D, Pornour M, Alivand MR. The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update. Cancer Chemother Pharmacol 2021;88:771-93. [PMID: 34510251 DOI: 10.1007/s00280-021-04337-8] [Reference Citation Analysis]
9 Jiang PF, Zhang XJ, Song CY, Zhang YX, Wu Y. S100P acts as a target of miR-495 in pancreatic cancer through bioinformatics analysis and experimental verification. Kaohsiung J Med Sci 2021;37:562-71. [PMID: 33949774 DOI: 10.1002/kjm2.12383] [Reference Citation Analysis]
10 Jamialahmadi K, Zahedipour F, Karimi G. The role of microRNAs on doxorubicin drug resistance in breast cancer. J Pharm Pharmacol 2021;73:997-1006. [PMID: 33942851 DOI: 10.1093/jpp/rgaa031] [Reference Citation Analysis]
11 Zangouei AS, Alimardani M, Moghbeli M. MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell Int 2021;21:213. [PMID: 33858435 DOI: 10.1186/s12935-021-01873-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Taheri M, Mahmud Hussen B, Tondro Anamag F, Shoorei H, Dinger ME, Ghafouri-Fard S. The role of miRNAs and lncRNAs in conferring resistance to doxorubicin. J Drug Target 2021;:1-21. [PMID: 33788650 DOI: 10.1080/1061186X.2021.1909052] [Reference Citation Analysis]
13 Wang H, Zhang K, Liu J, Yang J, Tian Y, Yang C, Li Y, Shao M, Su W, Song N. Curcumin Regulates Cancer Progression: Focus on ncRNAs and Molecular Signaling Pathways. Front Oncol 2021;11:660712. [PMID: 33912467 DOI: 10.3389/fonc.2021.660712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Toolabi N, Daliri FS, Mokhlesi A, Talkhabi M. Identification of key regulators associated with colon cancer prognosis and pathogenesis. J Cell Commun Signal 2021. [PMID: 33770351 DOI: 10.1007/s12079-021-00612-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ren FJ, Yao Y, Cai XY, Fang GY. Emerging Role of MiR-192-5p in Human Diseases. Front Pharmacol 2021;12:614068. [PMID: 33708127 DOI: 10.3389/fphar.2021.614068] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Yu DS, Song XL, Yan C. Oncogenic miRNA-1908 targets HDAC10 and promotes the aggressive phenotype of cervical cancer cell. Kaohsiung J Med Sci 2021;37:402-10. [PMID: 33493381 DOI: 10.1002/kjm2.12348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Liu LJ, Sun XY, Yang CX, Zou XY. MiR-10a-5p restrains the aggressive phenotypes of ovarian cancer cells by inhibiting HOXA1. Kaohsiung J Med Sci 2021;37:276-85. [PMID: 33332731 DOI: 10.1002/kjm2.12335] [Reference Citation Analysis]
18 Liang R, Zhang J, Zhang RM, Qiu H. LINC01315 silencing inhibits the aggressive phenotypes of colorectal carcinoma by sponging miR-205-3p. Biochem Biophys Res Commun 2021;534:1033-9. [PMID: 33162032 DOI: 10.1016/j.bbrc.2020.10.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Bazavar M, Fazli J, Valizadeh A, Ma B, Mohammadi E, Asemi Z, Alemi F, Maleki M, Xing S, Yousefi B. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells. Pathology - Research and Practice 2020;216:153176. [DOI: 10.1016/j.prp.2020.153176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
20 LaFavers KA, Macedo E, Garimella PS, Lima C, Khan S, Myslinski J, McClintick J, Witzmann FA, Winfree S, Phillips CL, Hato T, Dagher PC, Wu XR, El-Achkar TM, Micanovic R. Circulating uromodulin inhibits systemic oxidative stress by inactivating the TRPM2 channel. Sci Transl Med 2019;11:eaaw3639. [PMID: 31578243 DOI: 10.1126/scitranslmed.aaw3639] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
21 Mishan MA, Tabari MAK, Parnian J, Fallahi J, Mahrooz A, Bagheri A. Functional mechanisms of miR-192 family in cancer. Genes Chromosomes Cancer 2020. [PMID: 32706406 DOI: 10.1002/gcc.22889] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Flammang I, Reese M, Yang Z, Eble JA, Dhayat SA. Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1693. [PMID: 32630552 DOI: 10.3390/cancers12061693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
23 Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, Liu Z, Xu Q, Liu S, Xiao D, Tao Y. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer 2020;19:47. [PMID: 32122355 DOI: 10.1186/s12943-020-01171-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 14.5] [Reference Citation Analysis]
24 Li X, Strietz J, Bleilevens A, Stickeler E, Maurer J. Chemotherapeutic Stress Influences Epithelial-Mesenchymal Transition and Stemness in Cancer Stem Cells of Triple-Negative Breast Cancer. Int J Mol Sci 2020;21:E404. [PMID: 31936348 DOI: 10.3390/ijms21020404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
25 Zou P, Zhu M, Lian C, Wang J, Chen Z, Zhang X, Yang Y, Chen X, Cui X, Liu J, Wang H, Wen Q, Yi J. miR-192-5p suppresses the progression of lung cancer bone metastasis by targeting TRIM44. Sci Rep 2019;9:19619. [PMID: 31873114 DOI: 10.1038/s41598-019-56018-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
26 Shahriari M, Taghdisi SM, Abnous K, Ramezani M, Alibolandi M. Synthesis of hyaluronic acid-based polymersomes for doxorubicin delivery to metastatic breast cancer. International Journal of Pharmaceutics 2019;572:118835. [DOI: 10.1016/j.ijpharm.2019.118835] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
27 Zang S, Zhao S, Gao X, Li Y, Zhong C, Gao J. Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin. Onco Targets Ther 2019;12:7551-60. [PMID: 31686855 DOI: 10.2147/OTT.S212649] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]